Xvivo Perfusion AB
STO:XVIVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xvivo Perfusion AB
STO:XVIVO
|
SE |
|
Cooper Companies Inc
NASDAQ:COO
|
US |
|
Praxis Precision Medicines Inc
NASDAQ:PRAX
|
US |
|
Zalando SE
XETRA:ZAL
|
DE |
Xvivo Perfusion AB
Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted.
Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.
Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted.
Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.
Organic Growth: XVIVO reported 6% organic top-line growth in Q3 2025 when excluding U.S. heart trial revenue, highlighting steady progress despite market headwinds.
Segment Trends: Abdominal segment led with record performance (47% organic growth), while Thoracic sales fell due to lower heart trial revenue and softer lung market conditions.
Margins & Profitability: Gross margin was strong at 75% in Q3, and EBITDA margin recovered to 19% as sales rebounded from Q2 levels.
Cost Discipline: Operating expenses were tightly managed, down 2% year-on-year in Q3, supporting solid cash flow and a stable financial base.
US Market & Outlook: Management expects gradual recovery in U.S. lung activity and is investing in service partnerships and expanded clinical support to drive growth in the U.S. over the next five quarters.
Regulatory Updates: Heart approval in Europe remains the top priority; U.S. heart and liver filings continue, but the liver trial is paused to explore a potentially faster regulatory route.
Clinical Progress: XVIVO’s heart technology shows strong clinical results, and enrollment in key U.S. heart studies is ramping up, with more centers expected to join.
